X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PFIZER - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PFIZER AUROBINDO PHARMA/
PFIZER
 
P/E (TTM) x 13.9 30.9 44.9% View Chart
P/BV x 3.6 4.9 72.5% View Chart
Dividend Yield % 0.4 0.7 66.5%  

Financials

 AUROBINDO PHARMA   PFIZER
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
PFIZER
Mar-16
AUROBINDO PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs8952,724 32.9%   
Low Rs6221,611 38.6%   
Sales per share (Unadj.) Rs254.6440.9 57.7%  
Earnings per share (Unadj.) Rs39.348.7 80.7%  
Cash flow per share (Unadj.) Rs46.675.8 61.5%  
Dividends per share (Unadj.) Rs2.5015.00 16.7%  
Dividend yield (eoy) %0.30.7 47.6%  
Book value per share (Unadj.) Rs160.0462.9 34.6%  
Shares outstanding (eoy) m585.8845.75 1,280.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.9 60.6%   
Avg P/E ratio x19.344.5 43.4%  
P/CF ratio (eoy) x16.328.6 56.9%  
Price / Book Value ratio x4.74.7 101.3%  
Dividend payout %6.430.8 20.7%   
Avg Mkt Cap Rs m444,39099,163 448.1%   
No. of employees `00014.02.9 484.0%   
Total wages/salary Rs m17,6782,758 641.1%   
Avg. sales/employee Rs Th10,667.86,981.7 152.8%   
Avg. wages/employee Rs Th1,264.3954.5 132.5%   
Avg. net profit/employee Rs Th1,645.8771.1 213.4%   
INCOME DATA
Net Sales Rs m149,15720,170 739.5%  
Other income Rs m1,159857 135.2%   
Total revenues Rs m150,31621,028 714.9%   
Gross profit Rs m34,3434,310 796.9%  
Depreciation Rs m4,2761,239 345.2%   
Interest Rs m6675 12,830.8%   
Profit before tax Rs m30,5583,923 778.9%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m7,5971,794 423.3%   
Profit after tax Rs m23,0122,228 1,033.0%  
Gross profit margin %23.021.4 107.8%  
Effective tax rate %24.945.7 54.4%   
Net profit margin %15.411.0 139.7%  
BALANCE SHEET DATA
Current assets Rs m92,06216,299 564.8%   
Current liabilities Rs m66,2237,594 872.1%   
Net working cap to sales %17.343.2 40.1%  
Current ratio x1.42.1 64.8%  
Inventory Days Days10665 162.4%  
Debtors Days Days6826 262.8%  
Net fixed assets Rs m62,9198,622 729.8%   
Share capital Rs m586458 128.1%   
"Free" reserves Rs m93,13320,722 449.4%   
Net worth Rs m93,71921,180 442.5%   
Long term debt Rs m1,81425 7,256.0%   
Total assets Rs m162,49429,137 557.7%  
Interest coverage x46.8755.5 6.2%   
Debt to equity ratio x00 1,639.8%  
Sales to assets ratio x0.90.7 132.6%   
Return on assets %14.67.7 190.1%  
Return on equity %24.610.5 233.4%  
Return on capital %32.719.0 172.4%  
Exports to sales %00.1 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA12 0.0%   
Imports (cif) Rs mNA3,526 0.0%   
Fx inflow Rs m75,83852 146,830.0%   
Fx outflow Rs m30,224140 21,591.9%   
Net fx Rs m45,613-88 -51,639.8%   
CASH FLOW
From Operations Rs m32,7863,436 954.1%  
From Investments Rs m-17,870-6,991 255.6%  
From Financial Activity Rs m-19,153-619 3,095.1%  
Net Cashflow Rs m-4,239-4,174 101.6%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 8.0 7.5 106.0%  
FIIs % 27.7 4.9 565.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 23.7 43.0%  
Shareholders   69,601 85,207 81.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Metal Stocks Top Losers(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading marginally above the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 21, 2018 02:57 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS